Literature DB >> 7031542

Maternal and fetal effects of acetaminophen and salicylates in pregnancy.

E Collins.   

Abstract

Salicylates have been the most widely studied of the nonnarcotic analgesics in pregnancy, and in the last 20 years evidence has accumulated indicating that their ingestion in pregnancy may have adverse effects on the mother and her child. Salicylates have been found to reduce the mean birth weight of the offspring in animal studies and in 1 human study. In the third trimester of pregnancy the maternal and fetal effects are mediated through the antiprostaglandin properties of salicylates and include prolongation of gestation and labor, increased blood loss at delivery, and increased perinatal mortality. Bleeding manifestations and withdrawal symptoms in newborn infants are associated with raised fetal blood salicylate levels. These effects of salicylates warrant routine antenatal urinary screening for salicylates in communities known to use them heavily. Adverse maternal or fetal effects form acetaminophen use in pregnancy have not been reported, but formal clinical or epidemiologic studies of its use have not been conducted.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7031542

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  5 in total

1.  [Not Available].

Authors:  K Menges
Journal:  Schmerz       Date:  1987-09       Impact factor: 1.107

2.  [Not Available].

Authors:  K Strasser
Journal:  Schmerz       Date:  1988-06       Impact factor: 1.107

Review 3.  Non-narcotic analgesics. Use in pregnancy and fetal and perinatal effects.

Authors:  M A Heymann
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 4.  Migraine Treatment in Pregnancy and Lactation.

Authors:  Anne H Calhoun
Journal:  Curr Pain Headache Rep       Date:  2017-10-04

Review 5.  Long-term adverse effects of paracetamol - a review.

Authors:  J C McCrae; E E Morrison; I M MacIntyre; J W Dear; D J Webb
Journal:  Br J Clin Pharmacol       Date:  2018-07-20       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.